ISRCTN17072692已完成1 期
A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 192
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35043093/ (added 20/01/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36684396/ (added 24/01/2023) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/36194628/ Sub-study results (added 09/07/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy adults from the following age ranges:
- •1.1. For the dose escalation and evaluation, aged 18- 45 years on the day of screening
- •1.2. For the expanded safety evaluation, aged 18-75 years on the day of screening
- •2. At a similar risk of acquiring SARS-CoV2 infection to the general population
- •3. Willing and able to provide written informed consent
- •4. If female and of childbearing potential and not sterilised, willing to use a highly effective method of contraception from screening until 18 weeks after the last injection
- •5. If male and not sterilised, willing to avoid impregnating female partners from screening until 18 weeks after last injection
- •6. Willing to avoid all other vaccines 4 weeks after the first injection through to 4 weeks after the second injection
- •7. Willing and able to comply with visit schedule, complete online diaries and provide samples
- •8. Willing to grant authorised persons access to his/her trial-related medical record and GP records either directly or indirectly
排除标准
- •1. Pregnant or lactating
- •2. Presence of active systemic disease or pre-exisiting conditions that require investigation or a change to treatment that in the opinion of the investigator may compromise the volunteer’s safety, preclude vaccination or compromise interpretation of the immune response to vaccine
- •3. History of COVID-19 infection
- •4. History of severe or multiple allergies to drugs or pharmaceutical agents
- •5. History of severe local or general reaction to vaccination defined as:
- •5.1. Local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours
- •5.2. General: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours
- •6. Ever received an experimental vaccine against COVID-19
- •7. Receipt of any immunosuppressive agents within 18 weeks of screening by any route other than topical
- •8. Detection of antibodies to hepatitis C
- •9. Detection of antibodies to HIV
- •10. Grade 1 and above abnormalities in routine laboratory parameters (see Table 4) using the FDA toxicity table Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (https://www.fda.gov/media/73679/download)
- •11. Participating in another clinical trial with an investigational drug or device, or treated with an investigational drug within 28 days of screening
- •12. Has received an immunisation within 28 days of screening
研究者
相似试验
已完成
1 期
A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in relapsed/refractory cancers of children and young adultsCancerISRCTN21727048niversity of Birmingham49
已完成
2 期
To evaluate the safety and effectiveness of human ex vivo expanded autologous limbal stem cells for the treatment of unilateral total limbal stem cell deficiencyISRCTN51772481ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)24
已完成
1 期
C34-PEG-4-Chol - a new fusion inhibitor for the treatment of HIVISRCTN89747147Imperial College London42
招募中
不适用
First in Human Study to Assess the Safety and the Efficacy of an Implantable Nitinol Device in the Treatment of KeratoconusKeratoconusNCT06451718Fundacio De Recerca Del Instituto De Microcirugia Ocular12
终止
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsAdvanced TumorsNon-Small-Cell Lung CancerErdheim-Chester DiseaseMelanomaOther RAS/RAF/MEK/ERK Mutated TumorsNCT04198818Haihe Biopharma Co., Ltd.37